



D										
	Murine κB-site									
Bcl-xL	G	G	G	Α	С	Τ	Т	С	С	Α
Fas	G	G	G	Α	Α	Т	G	С	С	С
	G	G	G	Т	Т	Т	С	С	С	С
*COX2	G	G	G	G	Α	Т	Т	С	С	С
NOD2	G	G	G	Α	Α	Т	Т	Т	С	С
CSF1	G	G	G	Α	С	Т	Т	Т	С	С
$Gadd45\beta$	G	G	G	Α	С	Т	С	Т	С	С
	G	G	G	G	Α	Т	Т	С	С	Α
ΙκΒα	G	G	Α	Α	Α	Т	Т	С	С	С
	G	G	G	G	Α	Α	G	Т	С	С

Supplementary Figure 1. (A) U87 nuclear extracts, treated with 100  $\mu$ M TMZ or vehicle for 16 hours, were examined by immunoblot (IB) for the indicated NF- $\kappa$ B subunit and by EMSA for OCT-1 binding. Competition studies were used to demonstrate the specificity of the indicated band on EMSA (data not shown). (B and C) NF- $\kappa$ B EMSAs with the indicated probe in U87 cells. Supershift was performed with the antibodies shown. (B) Probes used include: GGGACTTTCC (-1C) or GGGAATTTCC (-1A) probe. (C) -1A probe was used following treatment with vehicle or 100  $\mu$ M TMZ. (D) Murine  $\kappa$ B-sites. \* Cox2 promoter  $\kappa$ B-site.

## **Supplemental Figure 1**



Supplementary Figure 2. Representative EMSA gels from competition assays using purified p50<sup>wt</sup> (upper) or p50<sup>S329D</sup> (lower). Radio-labeled -1A probe was used and increasing concentrations of unlabelled non-specific DNA (NS), -1C or -1A competitor DNA was added as described in methods.



Supplementary Figure 3. Differential expression of CSF1 and NOD2 following DNA damage. (A) Immunoblot of p105<sup>-/-</sup> MEF cells transiently transfected with empty vector (EV), p105<sup>wt</sup>, p105<sup>S329A</sup>, or p105<sup>S329D</sup>. (B) qPCR analysis of CSF1 and NOD2 mRNA expression in p105<sup>-/-</sup> MEFs expressing empty vector (EV), p105<sup>wt</sup>, p105<sup>S329A</sup>, or p105<sup>S329D</sup> following 16 hour treatment with 100  $\mu$ M TMZ (white bars) or vehicle (black bars). Data show mean values normalized to control  $\pm$  SEM of triplicate samples from three experiments.

Supplementary Table 1. Sequence of  $\kappa B$ -site probes used for EMSA.

κB-site	Sense Oligonucleotide Sequence
p50 half-site variants	GGGRNTTTCC
p65 half-site variants	GGGA (A/C) TYYCC
-1A κB-site	GGGAATTTCC
-1C κB-site	GGGACTTTCC
IgK	GGGACTTTCC
NOD2	GGGAATTTCC
Bax	GGGAATTCCA
IFN	GGGAAATTCC
TNF	GGGGCTTTCC
H2B	GGGGATTCCC
Bcl-xL	GGGACTGCCC
Fas	GGGAATGCCC
TAP1/LMP2	GGGACTTTCC
CSF1	GGGACTTTCC
ΙκΒα	GGAAATTCCC
Human Cox2	GGGACTACCC
Mouse Cox2 promoter κB-site	GGGGATTCCC
Mouse Cox2 intronic κB-site	GGGACTCCTC